Philadelphia shows no signs of relinquishing its place atop the national leaders in life sciences real estate and development. JLL has reported the Philadelphia market acts as a global anchor for the life sciences industry, while CBRE recently noted the city’s rapid ascension in the ranks of the country’s premier life sciences markets. Greater Philadelphia ranks among the top five metropolitan areas for National Institutes of Health funding, and the intensity of private investment continues unabated. In recent months, for example, developer J. Brian O’Neill paid $103 million for the former GlaxoSmithKline complex in Upper Merion with plans to build a network of life science space, and Silverstein Properties announced a $56 million investment in the development of 3.0 University Place, a proposed 250,000-square-foot life sciences building in University City.

Please join us for this moderated discussion of the local life sciences sector from a diverse range of panelist perspectives: architectural design, healthcare operations, and real estate investment. Our panelists will examine the value proposition offered in both the city and suburbs; discuss the latest amenities sought by life science tenants; and explore the origin and evolution of life science companies in Philadelphia and their deep connection to university and healthcare institutions in the region.

PANELISTS:
- Mark Seltzer, Senior VP, Development, East Region, Ensemble
- Dominique Casimir, MBA, VP, Real Estate, Thomas Jefferson Health & University Sys.
- Pete Cramer, Director of Development, Wexford Science + Technology
- Audrey Greenberg, Co-Founder, The Discovery Labs

MODERATED BY:
Mayva Donnon, Partner, KSS Architects